As of November 6, 2026, BioAge Labs, Inc. is a publicly traded company (Nasdaq: BIOA); its largest reported holder is Cormorant Asset Management, LP, with 5.38% on Schedule 13G/A of August 14, 2026, then BlackRock (5.03%) (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in BioAge Labs, Inc.? See the free Snapshot first.
Free to see. No signup.
Is BioAge Labs, Inc. a real, registered company?
- BioAge Labs, Inc. files with the SEC under CIK 1709941 (its SEC filings).
- Its shares are listed under the ticker BIOA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Emeryville, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under BioAge Labs, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Cormorant Asset Management, LP (filed 2026-08-14).
Who are BioAge Labs, Inc.'s owners and officers?
BioAge Labs, Inc.: incorporated in Delaware; business address in Emeryville, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-02-13)
- : Director (Form D, 2024-02-13)
- : Director (Form D, 2024-02-13)
- : Director (Form D, 2024-02-13)
- : Director (Form D, 2024-02-13)
- : Director (Form D, 2024-02-13)
- : Director (Form D, 2024-02-13)
- : Executive Officer (Form D, 2024-02-13)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Cormorant Asset Management, LP | 5.38% |
| Schedule 13G/A, 2026-05-15 | Vk Services, LLC | 4% |
| Schedule 13G/A, 2026-05-15 | Cormorant Asset Management, LP | 6.51% |
| Schedule 13G, 2026-04-27 | Blackrock, Inc. | 5.03% |
| Schedule 13G/A, 2026-02-17 | Adar1 Capital Management, LLC | 0.4% |
| Schedule 13G/A, 2026-02-17 | Cormorant Asset Management, LP | 5.69% |
| Schedule 13G/A, 2026-02-13 | Kristen Fortney | 7.2% |
| Schedule 13G/A, 2025-08-14 | Cormorant Asset Management, LP | 5.97% |
| Schedule 13G, 2025-08-14 | Adar1 Capital Management, LLC | 5.4% |
Questions about who owns BioAge Labs, Inc.
Who owns BioAge Labs, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of BioAge Labs, Inc.: Kristen Fortney (7.2%, Schedule 13G/A, filed 2026-02-13), Cormorant Asset Management, LP (5.38%, Schedule 13G/A, filed 2026-08-14) and Blackrock, Inc. (5.03%, Schedule 13G, filed 2026-04-27).
Who are the largest shareholders of BioAge Labs, Inc.?
By the share each holder's latest filing reports, the largest holders of BioAge Labs, Inc. on this page are Kristen Fortney (7.2%), Cormorant Asset Management, LP (5.38%) and Blackrock, Inc. (5.03%).
When did Kristen Fortney buy into BioAge Labs, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Kristen Fortney on this page is the Schedule 13G/A, filed 2026-02-13, reporting 7.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on BioAge Labs, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BioAge Labs, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioAge Labs, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own BioAge Labs, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 3,233,170 shares (7.0% of shares outstanding), held indirectly through Andreessen Horowitz LSV Fund III, L.P. and 2 others (Form 4, 2024-10-03).
- Bihua Chen: 1,629,529 shares (3.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2024-10-01).
- Cormorant Private Healthcare Fund IV LP: 1,629,529 shares (3.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2024-10-01).
- Cormorant Asset Management, LP: 1,629,529 shares (3.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2024-10-01).
- Cormorant Private Healthcare Fund V LP: 1,629,529 shares (3.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2024-10-01).
Shares outstanding: 45,958,509 as of 2026-10-30, from the company's latest SEC cover page.
How much has BioAge Labs, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-02-13 | $194.39M | $194.39M |
Latest IPO step: BioAge Labs, Inc. filed its final IPO prospectus (424B4, 2024-09-26).
IPO filings: 424B4, 2024-09-26, S-1/A, 2024-09-25, S-1/A, 2024-09-18, S-1, 2024-09-03.
Keep reading
More on BioAge Labs, Inc. and the records around it.
BioAge Labs, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Khosla Ventures VI, LP also filed stake reports on 2 other companies: Faeth Therapeutics, Inc. (Aug 2026), Serve Robotics Inc. (Sep 2025)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), Bright Minds Biosciences Inc. (Aug 2026)
- ADAR1 Capital Management, LLC also filed stake reports on 29 other companies: InMed Pharmaceuticals, Inc. (Oct 2026), Tenax Therapeutics, Inc. (Sep 2026), Adagio Medical Holdings, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/bioage-labs